Tag Archives: Difei Yang

Mizuho Securities Maintains Their Hold Rating on Audentes Therapeutics

Mizuho Securities analyst Difei Yang maintained a Hold rating on Audentes Therapeutics (NASDAQ: BOLD) today and set a price target of $38. The company’s shares closed on Friday at $38.24, close to its 52-week high of $42.61. Yang commented: “We

Mizuho Securities Keeps a Buy Rating on FibroGen

Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (NASDAQ: FGEN) today and set a price target of $61. The company’s shares closed yesterday at $49.70. Yang noted: “We expect to see top-line phase 3 data from Disease

Mizuho Securities Reaffirms Their Buy Rating on Heron Therapeutics

Mizuho Securities analyst Difei Yang maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX) today and set a price target of $35. The company’s shares closed yesterday at $29.75, close to its 52-week high of $32.70. Yang observed: “We believe

Viewray Received its Third Buy in a Row

After B.Riley FBR and Cantor Fitzgerald assigned a Buy rating to Viewray in the last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Viewray (NASDAQ: VRAY) today and set

Mizuho Securities Sticks to Its Buy Rating for Zogenix

Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (NASDAQ: ZGNX) today and set a price target of $51. The company’s shares closed yesterday at $39.40. Yang noted: “We are confident ahead of this data and we expect

Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $9.51, close to its 52-week low of $8.93. According